Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Lock

Showing results (141-150 of 220) with videos related to

Pageof 22
Sort By:
Haematologica|July 2, 2015
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient miceErwin M Lee, Dean Yee, Samantha J Busfield, et al.
Blood Advances|January 24, 2020
Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemiaHannah McCalmont, Ka Leung Li, Luke Jones, et al.
Pediatric Blood & Cancer|July 4, 2012
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing ProgramHernan Carol, C Patrick Reynolds, Min H Kang, et al.
Cancer Research|June 16, 2016
Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic BirinapantJennifer Richmond, Alissa Robbins, Kathryn Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing programMalcolm A Smith, C Patrick Reynolds, Min H Kang, et al.
Haematologica|February 15, 2024
<i>ETV6::ACSL6</i> translocation-driven super-enhancer activation leads to eosinophilia in acute lymphoblastic leukemia through IL-3 overexpressionWenqian Xu, Feng Tian, Xiaolu Tai, et al.
Experimental Hematology|February 6, 2024
In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenograftsJoanna Randall, Kathryn Evans, Ben Watts, et al.
Pediatric Blood & Cancer|December 27, 2019
Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemiaJinhan Xie, Miriam Span, Erik van Maarseveen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2015
Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemiaJennifer Richmond, Hernan Carol, Kathryn Evans, et al.
Bone Marrow Transplantation|May 17, 2016
Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALLT N Trahair, R B Lock, R Sutton, et al.
Pageof 22

Showing results (141-150 of 220) with videos related to

Sort By:
Pageof 22
Haematologica|July 2, 2015
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient miceErwin M Lee, Dean Yee, Samantha J Busfield, et al.
Blood Advances|January 24, 2020
Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemiaHannah McCalmont, Ka Leung Li, Luke Jones, et al.
Pediatric Blood & Cancer|July 4, 2012
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing ProgramHernan Carol, C Patrick Reynolds, Min H Kang, et al.
Cancer Research|June 16, 2016
Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic BirinapantJennifer Richmond, Alissa Robbins, Kathryn Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing programMalcolm A Smith, C Patrick Reynolds, Min H Kang, et al.
Haematologica|February 15, 2024
<i>ETV6::ACSL6</i> translocation-driven super-enhancer activation leads to eosinophilia in acute lymphoblastic leukemia through IL-3 overexpressionWenqian Xu, Feng Tian, Xiaolu Tai, et al.
Experimental Hematology|February 6, 2024
In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenograftsJoanna Randall, Kathryn Evans, Ben Watts, et al.
Pediatric Blood & Cancer|December 27, 2019
Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemiaJinhan Xie, Miriam Span, Erik van Maarseveen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2015
Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemiaJennifer Richmond, Hernan Carol, Kathryn Evans, et al.
Bone Marrow Transplantation|May 17, 2016
Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALLT N Trahair, R B Lock, R Sutton, et al.
Pageof 22